The DOI matches its Crossref record; 13 of the 14 references it cites were found in a registry or an index, and 1 are not checked yet.
Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in children and infants: two clinical trials
Open accessAbstract
BACKGROUND: Continued emergence and spread of circulating vaccine-derived type 2 polioviruses and vaccine-associated paralytic poliomyelitis from Sabin oral poliovirus vaccines (OPVs) has stimulated development of two novel type 2 OPV candidates (OPV2-c1 and OPV2-c2) designed to have similar immunogenicity, improved genetic stability, and less potential to reacquire neurovirulence. We aimed to assess safety and immunogenicity of the two novel OPV candidates compared with a monovalent Sabin OPV in children and infants. METHODS: We did two single-centre, multi-site, partly-masked, randomised trials in healthy cohorts of children (aged 1-4 years) and infants (aged 18-22 weeks) in Panama: a control phase 4 study with monovalent Sabin OPV2 before global cessation of monovalent OPV2 use, and a phase 2 study with low and high doses of two novel OPV2 candidates. All participants received one OPV2 vaccination and subsets received two doses 28 days apart. Parents reported solicited and unsolicited adverse events. Type 2 poliovirus neutralising antibodies were measured at days 0, 7, 28, and 56, and stool viral shedding was assessed up to 28 days post-vaccination. Primary objectives were to assess safety in all participants and non-inferiority of novel OPV2 day 28 seroprotection versus monovalent OPV2 in infants (non-inferiority margin 10%). These studies were registered with ClinicalTrials.gov, NCT02521974 and NCT03554798. FINDINGS: The control study took place between Oct 23, 2015, and April 29, 2016, and the subsequent phase 2 study between Sept 19, 2018, and Sept 30, 2019. 150 children (50 in the control study and 100 of 129 assessed for eligibility in the novel OPV2 study) and 684 infants (110 of 114 assessed for eligibility in the control study and 574 of 684 assessed for eligibility in the novel OPV2 study) were enrolled and received at least one study vaccination. Vaccinations were safe and well tolerated with no causally associated serious adverse events or important medical events in any group. Solicited and unsolicited adverse events were overwhelmingly mild or moderate irrespective of vaccine or dose. Nearly all children were seroprotected at baseline, indicating high baseline immunity. In children, the seroprotection rate 28 days after one dose was 100% for monovalent OPV2 and both novel OPV2 candidates. In infants at day 28, 91 (94% [95% CI 87-98]) of 97 were seroprotected after receiving monovalent OPV2, 134 (94% [88-97]) of 143 after high-dose novel OPV2-c1, 122 (93% [87-97]) of 131 after low-dose novel OPV2-c1, 138 (95% [90-98]) of 146 after high-dose novel OPV2-c2, and 115 (91% [84-95]) of 127 after low-dose novel OPV2-c2. Non-inferiority was shown for low-dose and high-dose novel OPV2-c1 and high-dose novel OPV2-c2 despite monovalent OPV2 recipients having higher baseline immunity. INTERPRETATION: Both novel OPV2 candidates were safe, well tolerated, and immunogenic in children and infants. Novel OPV2 could be an important addition to our resources against poliovirus given the current epidemiological situation. FUNDING: Fighting Infectious Diseases in Emerging Countries and Bill & Melinda Gates Foundation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Phase 2 trials showed that the new vaccines were well tolerated and induced an immune response like that of the existing monovalent vaccine in an adult population with a history of OPV vaccination, as well as in children and infants [123,124].”
From The Fight against Poliovirus Is Not Over (2023) · cites this paper as [124]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Burns, C. C., Diop, O. M., Sutter, R. W., & Kew, O. M. (2014) · Journal of Infectious Diseases · doi:10.1093/infdis/jiu295 · Cited by 309
Engineering the Live-Attenuated Polio Vaccine to Prevent Reversion to Virulence
Yeh, M. T., Bujaki, E., Dolan, P. T., Smith, M., Wahid, R., Konz, J., Weiner, A. J., Bandyopadhyay, A. S., Van Damme, P., De Coster, I., et al. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2020.04.003 · Cited by 221
Self-citationHampton, L. M., Farrell, M., Ramirez-Gonzalez, A., Menning, L., Shendale, S., Lewis, I., Rubin, J., Garon, J., Harris, J., Hyde, T., et al. (2016) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6535a3 · Cited by 193
Macklin, G., O’Reilly, K. M., Grassly, N. C., Edmunds, W. J., Mach, O., Krishnan, R. S. G., Voorman, A., Vertefeuille, J. F., Abdelwahab, J., Gumede, N., et al. (2020) · Science · doi:10.1126/science.aba1238 · Cited by 156
Self-citationVan Damme, P., De Coster, I., Bandyopadhyay, A. S., Revets, H., Withanage, K., De Smedt, P., Suykens, L., Oberste, M. S., Weldon, W. C., Costa-Clemens, S. A., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31279-6 · Cited by 141
Self-citationStandardized Methods for Detection of Poliovirus Antibodies
Weldon, W. C., Oberste, M. S., & Pallansch, M. A. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-3292-4_8 · Cited by 128
Self-citationDevelopment of a new oral poliovirus vaccine for the eradication end game using codon deoptimization
Konopka‐Anstadt, J. L., Campagnoli, R. P., Vincent, A., Shaw, J., Wei, L., Wynn, N. T., Smithee, S., Bujáki, E., Yeh, M. T., Laassri, M., et al. (2020) · npj Vaccines · doi:10.1038/s41541-020-0176-7 · Cited by 104
Self-citationUpdate on Vaccine-Derived Poliovirus Outbreaks — Worldwide, July 2019–February 2020
Alleman, M. M., Jorba, J. C., Greene, S. A., Diop, O. M., Iber, J. C., Tallis, G. F., Goel, A., Wiesen, E., Wassilak, S. G. F., & Burns, C. C. (2020) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6916a1 · Cited by 102
De Coster, I., Leroux-Roels, I., Bandyopadhyay, A. S., Gast, C., Withanage, K., Steenackers, K., De Smedt, P., Aerssens, A., Leroux-Roels, G., Oberste, M. S., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32541-1 · Cited by 86
Self-citationAsturias, E. J., Bandyopadhyay, A. S., Self, S., Rivera, L., Saez-Llorens, X., Lopez, E., Melgar, M., Gaensbauer, J. T., Weldon, W. C., Oberste, M. S., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00703-0 · Cited by 80
Self-citation
Research works printed but not linked: 1
- 2020, Meeting of the strategic advisory group of experts on immunization, 31 March–1 April 2020: conclusions and recommendations: polio, Wkly Epidemiol Rec, 22, 249
Cited by
De Coster, I., Leroux-Roels, I., Bandyopadhyay, A. S., Gast, C., Withanage, K., Steenackers, K., De Smedt, P., Aerssens, A., Leroux-Roels, G., Oberste, M. S., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32541-1 · Cited by 86
Self-citationAdvanced oral vaccine delivery strategies for improving the immunity
Zhang, Y., Li, M., Du, G., Chen, X., & Sun, X. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113928 · Cited by 80
Macklin, G., Peak, C. M., Eisenhawer, M., Kurji, F., Mach, O., Konz, J., Gast, C., Bachtiar, N. S., Bandyopadhyay, A. S., & Zipursky, S. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.02.050 · Cited by 72
Self-citationMucosal immunity to poliovirus
Connor, R. I., Brickley, E. B., Wieland‐Alter, W., Ackerman, M. E., Weiner, J. A., Modlin, J. F., Bandyopadhyay, A. S., & Wright, P. F. (2021) · Mucosal Immunology · doi:10.1038/s41385-021-00428-0 · Cited by 71
Self-citationGenetic stabilization of attenuated oral vaccines against poliovirus types 1 and 3
Yeh, M. T., Smith, M. R., Carlyle, S., Konopka‐Anstadt, J. L., Burns, C. C., Konz, J., Andino, R., & Macadam, A. J. (2023) · Nature · doi:10.1038/s41586-023-06212-3 · Cited by 66
Self-citation
Metadata
- Authors
- Sáez-Llorens, X., Bandyopadhyay, A. S., Gast, C., Leon, T. D., DeAntonio, R., Jimeno, J., Caballero, M. I., Aguirre, G., Oberste, M. S., Weldon, W. C., Konopka-Anstadt, J. L., Modlin, J., Bachtiar, N. S., Fix, A., Konz, J., Clemens, R., Costa Clemens, S. A., & Rüttimann, R.
- Affiliations
- Gates Foundation (US)
- Program for Appropriate Technology in Health (US)
- CEVAXIN (PA)
- VaxTrials (Panama) (PA)
- Fighting Infectious Diseases in Emerging Countries (US)
- Centers for Disease Control and Prevention (US)
- Dartmouth College (US)
- PT Bio Farma (Indonesia) (ID)
- Corresponding author
- Rüttimann, Ricardo
- ORCID
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2021-01
- Volume
- 397
- Issue
- 10268
- Pages
- 27-38
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- PMC
- PMC7811205
- OpenAlex
- W4254537929
- Cited by
- 81
- References
- 13
- Citations by year
- 2026: 5 · 2025: 15 · 2024: 13 · 2023: 18 · 2022: 16 · 2021: 12
- FWCI
- 7.43
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by/4.0/ (vor)
- Locations
- The Lancet (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Greater South Information System
- Funders
- Eli Lilly and Company
- Centers for Disease Control and Prevention
- Pan American Health Organization
- Topics
- Health Sciences › Medicine › Infectious Diseases › Viral Infections and Immunology Research
- Health Sciences › Medicine › Epidemiology › Virology and Viral Diseases
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- oral polio vaccine, poliovirus type 2, vaccine safety, immunogenicity, vaccine-associated paralytic poliomyelitis, infants, children
- MeSH terms
- Antibodies, Viral, Antibody Formation, Child, Preschool, Female, Humans, Immunization Schedule, Infant, Male, Panama, Poliomyelitis, Poliovirus Vaccine, Inactivated, Poliovirus Vaccine, Oral, Vaccination, Virus Shedding, Poliovirus, Patient Safety
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in children and infants: two clinical trials. https://app.cochat.ai/papers/10.1016/s0140-6736(20)32540-x
- The paper
- Sáez-Llorens, X., Bandyopadhyay, A. S., Gast, C., Leon, T. D., DeAntonio, R., Jimeno, J., Caballero, M. I., Aguirre, G., Oberste, M. S., Weldon, W. C., Konopka-Anstadt, J. L., Modlin, J., Bachtiar, N. S., Fix, A., Konz, J., Clemens, R., Costa Clemens, S. A., & Rüttimann, R. (2021). Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in children and infants: two clinical trials. The Lancet. https://doi.org/10.1016/s0140-6736(20)32540-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.